May 17, 2020

Ebola Crisis: Novarum DX is Responding With an mHealth App That Detects the Disease

Ebola
mHealth
apps
Novarum DX
Admin
3 min
Community engagement is key to successfully controlling outbreaks.
Novarum DX, the worlds leading mobile point of care technology company specialising in creating smartphone apps for reading and sharing diagnostic test...

Novarum DX, the world’s leading mobile point of care technology company specialising in creating smartphone apps for reading and sharing diagnostic test results, has announced it will demo a newly created app which reads a rapid, point of care Ebola test.

Novarum DX is well known within the mHealth marketplace for creating applications to detect results from diagnostic assays, examples being tests for HIV, Legionella, Drugs of Abuse and Bowel Disease, working in close cooperation with some of the world’s leading diagnostics companies.

Building on a simple-to-use diagnostic test from specialist defence diagnostic manufacturer BBI Detection, Novarum DX has developed an application to read and share the results of BBI’s Ebola test, using nothing but a smartphone. This first of its kind app will be demonstrated at the GSMA Mobile World Congress March 2-5, 2015, in Barcelona, Spain.

[READ MORE] This Ebola Outbreak Might Not Go Away For A Very Long Time

“With over 23,000 cases globally, over 9,000 Ebola related deaths, and concern over misdiagnosis due to the symptom similarities with malaria, it is clear that something needs to be done to make testing for Ebola simpler and more accessible. One of the issues with point of care testing is the human error risk involved in visually reading a test. Another is the delay in sending tests to a lab for confirmation. Our application addresses both of these issues," said Neil Polwart, managing director of the company.    

“We are excited to be part of something that really could make a difference to a global crisis. Whether the app is used in West Africa where facilities are limited, for precautionary measures at border control, or indeed to track positive cases of the virus globally, we believe that this simple to use, low cost technology has the potential to impact the spread of Ebola in a very positive way," he added.

“We are encouraged by the pace at which the global diagnostics industry has responded to the Ebola crisis.  2015 has already seen one of our customers launch a home-use app, created for them by our specialist team, and we expect this year will also see a key Novarum customer achieve FDA clearance of one of our reader solutions. And so, whether in the developed or developing world, we believe Novarum’s technology is about to trigger a revolution in true point of care testing,” said Nicole Irvine, market development manager. 

[READ MORE] Will J&J Win the Race to Create an Ebola Virus Vaccine?

The Novarum Reader is a powerful software solution that lets you read and share the results of diagnostic assays (including lateral flow tests) using nothing more than a smartphone.

This unique, world-leading technology can be used by anyone, anywhere, with minimal training: connecting patients and doctors, field workers and lab researchers, and primary care individual clinicians to specialist practices.

It's powerful, fast, and secure, putting reliable results in the hands of the people who need them.

You can visit Novarum DX at Mobile World Congress from March 2-5 in Hall 7, Booth 7B11. To set up a meeting at the Congress, please email [email protected]

Follow us on Twitter (@HealthcareGlbl) and like us on Facebook!

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article